iSpecimen Inc. Amortization of Debt Issuance Costs and Discounts
iSpecimen Inc. (ISPC) reported Amortization of Debt Issuance Costs and Discounts of $4.45 thousand for the 9-month period ending 2024-09-30, per its 10-Q filed 2025-11-17.
Financial Statements › Cash Flow › Operating Activities
us-gaap:AmortizationOfFinancingCostsAndDiscounts · last filed 2025-11-17
- iSpecimen Inc. amortization of debt issuance costs and discounts for the quarter ending 2021-12-31 was $0.00, a 100.00% decline year-over-year.
- iSpecimen Inc. amortization of debt issuance costs and discounts for the quarter ending 2021-09-30 was $0.00, a 100.00% decline year-over-year.
- iSpecimen Inc. amortization of debt issuance costs and discounts for the quarter ending 2021-06-30 was $0.00.
- iSpecimen Inc. amortization of debt issuance costs and discounts for the quarter ending 2021-03-31 was $1.09K.
- iSpecimen Inc. amortization of debt issuance costs and discounts for fiscal 2021 was $1.09K, a 99.24% decline from fiscal 2020.
- iSpecimen Inc. amortization of debt issuance costs and discounts for fiscal 2020 was $143.44K.
| Period end | Amortization of Debt Issuance Costs and Discounts 3 month | Amortization of Debt Issuance Costs and Discounts 6 month | Amortization of Debt Issuance Costs and Discounts 9 month | Amortization of Debt Issuance Costs and Discounts 12 month |
|---|---|---|---|---|
| 2024-09-30 | $4.45K 10-Q · filed 2025-11-17 | |||
| 2021-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-03-30 | $0.00 derived: sum of 2 quarters · filed 2023-03-30 | $0.00 derived: sum of 3 quarters · filed 2023-03-30 | $1.09K 10-K/A · filed 2023-03-30 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $0.00 derived: sum of 2 quarters · filed 2022-11-08 | $1.09K 10-Q · filed 2022-11-08 | $2.90K derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $1.09K 10-Q · filed 2022-08-04 | $2.90K derived: sum of 3 quarters · filed 2022-08-04 | $5.29K derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $1.09K 10-Q · filed 2022-05-10 | $2.90K derived: sum of 2 quarters · filed 2022-05-10 | $5.29K derived: sum of 3 quarters · filed 2022-05-10 | |
| 2020-12-31 | $1.81K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-22 | $4.20K derived: sum of 2 quarters · filed 2022-03-22 | $143.44K 10-K · filed 2022-03-22 | |
| 2020-09-30 | $2.40K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $141.63K 10-Q · filed 2021-11-04 | ||
| 2020-06-30 | $139.23K 10-Q · filed 2021-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| OneMedNet Corp (ONMD) | $0.042B | ||
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |